Youngest Living Donor Liver Transplant for End‐Stage Liver Disease in a 6‐Month‐Old With a Novel Aggressive Mutation in KIF12 Gene.

Background: Kinesin family member 12 (KIF12) mutation‐related cholestatic disorder represents a rare subtype of progressive familial intrahepatic cholestasis (PFIC), referred to as PFIC Type 8, with only 21 reported cases globally to date. Methods: Here, we present a unique case of a 6‐month‐old boy diagnosed with homozygous KIF12 gene mutation, who successfully underwent a living donor liver transplant at our center for end‐stage liver disease. Results: This case marks the youngest patient of KIF12‐related cholestatic disorder necessitating a liver transplant to date. The child initially presented with neonatal cholestasis and then developed infantile hepatic decompensation. Our report discusses the diagnostic process and management strategies employed. It underscores the importance of prompt diagnosis through clinical suspicion, biochemical parameters, and genetic testing, as well as the adoption of suitable management strategies, including the early contemplation of liver transplant in such exceptional and rare cases of genetic intrahepatic cholestasis. Conclusion: KIF12‐related genetic disease should be considered in neonatal cholestasis cases with high gamma glutamyl transpeptidase to differentiate from conditions like biliary atresia. Favorable outcomes post liver transplant stress the importance of early genetic testing and referral to liver transplant centers for unresponsive patients, potentially saving lives. [ABSTRACT FROM AUTHOR]